Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate
  • Clinical Data

Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

BioSpace

If Biogen has shown that tau can impact cognition, Denali's technology--validated with an FDA approval in Hunter syndrome--could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

pharminent May 15, 2026

BioSpace

If Biogen has shown that tau can impact cognition, Denali’s technology–validated with an FDA approval in Hunter syndrome–could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Genmab drops 2 antibody assets, including another ProfoundBio ADC
Next: ECO 2026: tirzepatide shows potential for T1D treatment

Related Stories

  • Clinical Data

Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

pharminent July 14, 2026
  • Clinical Data

Major trial launched to explore GLP-1 benefit in dementia

pharminent July 13, 2026
  • Clinical Data

GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China

pharminent July 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.